Loading...
•
Jun 30, 2020
scPharmaceuticals Q2 2020 Earnings Report
Reported second quarter 2020 financial results and provided a business update.
Key Takeaways
scPharmaceuticals reported a net loss of $8.3 million for the second quarter of 2020. The company's cash, cash equivalents, restricted cash, and investments totaled over $119 million as of June 30, 2020.
FDA accepted for review the Company’s New Drug Application (NDA) resubmission for FUROSCIX and has set a Prescription Drug User-Fee Act (PDUFA) target action date of December 30, 2020
Raised gross proceeds of approximately $53.8 million through an underwritten offering of common stock
Current cash, cash equivalents, restricted cash, and investments to over $119 million as of June 30, 2020
Net loss for the second quarter of 2020 was $8.3 million
Forward Guidance
The Company expects the net loss for 2020 to be in the range of $36.0 to $40.0 million for the fiscal year.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...